Patients can engage in gamified versions of objective behavioural activities on a tablet. Credit: © 2025 Department of Psychiatry, Warneford Hospital, Oxford, OX3 7JX. Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with borderline personality disorder (BPD) using new technology. The study will offer insights into the daily experiences of individuals with psychiatric disorders. It aims to assess the acceptability of new technology designed to quantify the mood, behaviour and activity of the brain, and aid new therapeutic research and development. The NeuLogiq neuroassessment platform from Cumulus will be leveraged in the BPD patient population for the first time. It allows for brain function tracking over time, both in clinical settings and in patients’ homes. The NeuLogiq headset enables individuals to engage in gamified versions of objective behavioural activities on a tablet. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The headset measures electroencephalogram (EEG) brain wave patterns that are accurately synchronised with the activities. The goal is to capture data that offers a clearer understanding of the activity within the brain’s networks. The Department of Psychiatry at the University of Oxford will carry out the study at Warneford Hospital, gathering frequent EEG and behavioural evaluations and remote metrics of mood and activity. The study targets young adults aged 18 to 35 years and aims to evaluate the Cumulus platform’s feasibility in this population to offer a dataset for in-depth analysis of brain activity and behaviour in BPD. 30 BPD subjects and 20 subjects who have not been diagnosed with mental health disorders will be recruited. Boehringer Ingelheim neuroscience and mental health global head and senior vice-president Dr Hugh Marston stated: “If this platform is successfully validated in this patient population, it could be a game-changer for studies investigating novel precision psychiatry treatments. It could help us identify biomarkers for stratification and provide a rich dataset for reverse translation.” Boehringer recently entered a strategic research partnership with Cue Biopharma to develop and commercialise Cue’s CUE-501 product candidate for autoimmune conditions.

2025-04-25

·PMLiVE

Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines for hard-to-treat cancers. The research collaboration and global licence agreement will focus on developing treatments targeting tumours that are dependent on alternative lengthening of telomeres (ALT) for their growth. ALT is thought to occur in up to 10% of all cancers and is associated with poorer clinical outcomes and a lack of targeted therapies. Tessellate Bio has already developed inhibitors of an undisclosed target that helps enable the uncontrolled growth of ALT-positive cancer cells. Blocking this target has been shown to increase DNA damage, replication stress and tumour cell death in these tumour cells, and a “clear benefit” of the approach is that it does not affect healthy cells, according to the precision oncology company. The partners will work together to advance the programme, with Tessellate Bio eligible for near-term payments comprising an upfront licence fee, research funding and technical milestone payments, as well as downstream success-based milestones. Lamine Mbow, global head of discovery research at Boehringer, said the company is “[looking] forward to working with Tessellate Bio’s team of scientists to develop innovative cancer treatments based on their synthetic lethality approach targeting ALT-positive tumours”. Tessellate’s chief executive officer, Andree Blaukat, outlined that its partnership with Boehringer is its “first pharma collaboration”. “[Boehringer] has a proven commitment to oncology and the agreement aligns with our collaborative strategy for bringing new targeted treatment options based on the concept of synthetic lethality to patients across a wider range of cancers,” Blaukat said. The collaboration comes just over a week after Boehringer and Cue Biopharma announced a partnership worth $357m to develop and commercialise Cue’s pre-clinical B cell depletion therapy, CUE-501, for autoimmune diseases. Boehringer also partnered with Salipro Biotech last month to accelerate the development of multiple drug targets. The research and licence agreement will focus on advancing therapeutic solutions that target G protein-coupled receptors, ion channels, transporters and other integral membrane proteins in areas such as cardio-renal-metabolic diseases and mental health.

引进/卖出细胞疗法

2025-04-21

·勃林格殷格翰中国

勃林格进一步加强在自免及炎症、肿瘤等领域的研发布局

勃林格殷格翰与Cue Biopharma合作研发新一代自身免疫及炎症性疾病治疗药物近日，勃林格殷格翰与Cue Biopharma公司（纳斯达克代码：CUE）宣布达成战略合作并签署许可协议，以开发并商业化Cue Biopharma的在研分子CUE-501——一种具有独特优势的B细胞清除疗法，用以治疗自身免疫性疾病。Cue Biopharma是一家处于临床阶段的生物制药公司，致力于开发一种新型治疗性生物制剂，通过有针对性地激活和调节疾病特异性T细胞，治疗自身免疫及炎症性疾病。Cue Biopharma的这个处于临床前阶段的候选分子可结合B细胞特异性膜蛋白，选择性衔接针对病毒特异性记忆杀伤性T细胞，使其能选择性地清除B细胞，抑制自身免疫和炎症过程。与其他靶向B细胞的治疗方案相比，可能具有更好的疗效和安全性。Carine Boustany勃林格殷格翰美国研发基地负责人、全球免疫和呼吸疾病研究负责人这次合作标志着勃林格殷格翰在自身免疫及炎症性疾病的产品管线组合的战略性扩张，目前这一领域仍然面临挑战，患者通常需要经历多轮治疗才能有所缓解。借助Cue Biopharma自主研发的T细胞衔接器平台，我们的目标是为患者提供更早介入、更有效的诊疗方案。根据协议条款，Cue Biopharma的技术将被用于进一步研究和推进候选分子的开发。这项多年合作的条款还包括双方有能力将研究和潜在开发扩展到各种针对 B 细胞的双特异性抗体，涵盖自身免疫性疾病领域。此外，根据合作协议的条款，Cue Biopharma可获得1200万美金的预付款和研究支持资金。除此之外，Cue Biopharma还有资格获得达成研究、开发和商业化阶段所对应的总计约3.45亿美元的里程碑付款（首先是两个临床前开发阶段的里程碑付款以及基于净销售额的特许权使用费）。勃林格殷格翰增强ADC产品管线布局，NBE Therapeutics新研发中心在巴塞尔启用本月初，勃林格殷格翰旗下的全资子公司NBE Therapeutics在巴塞尔正式启动了其全新的抗体药物偶联物（ADC）研发中心。这一新的里程碑进一步彰显了公司对肿瘤领域创新投入的决心，也巩固了勃林格殷格翰在瑞士生物科技创新生态体系中的重要地位。NBE Therapeutics是一家创立于2012年的瑞士生物科技公司，2020年被勃林格殷格翰收入旗下，在公司的肿瘤研究战略中具有至关重要的作用。新投用的研发中心将成为推动ADC研发的旗舰研究中心，支持勃林格殷格翰开发革命性的肿瘤疗法，为全球患者带来改变生命的治疗。本次对NBE公司巴塞尔办公场地的投资，标志着勃林格殷格翰推动肿瘤诊疗变革的重要一步，将进一步巩固公司已经较为完善的肿瘤治疗管线。不久前，我们还与阿姆斯特丹的Synaffix B.V.公司达成许可协议，同时在奥地利维也纳的肿瘤研究中心启用了新的设施。此次巴塞尔新建的研发中心将助力构建广泛的ADC产品管线，探索肿瘤治疗新靶点，开发下一代癌症疗法。NBE Therapeutics专注开发下一代ADC产品，这类产品能将抗癌药物靶向递送到肿瘤细胞，同时减少对健康组织的影响。ADC结合了抗体的特异性和细胞毒性物质的治疗活性，为癌症治疗带来极具前景的新选择，将大大改善患者生活质量。新建的研发中心承载着未来几年我们对ADC研发追加2700万瑞士法郎的投资承诺，旨在打造先进成熟的科研环境，加速创新ADC疗法的开发，借助勃林格殷格翰庞大的肿瘤专家人才网络，汇集科研英才，形成研发合力。关于勃林格殷格翰勃林格殷格翰是全球领先的生物制药企业，布局人用药品、动物保健两大业务领域。公司研发投入位居行业前列，致力于研究突破性疗法，解决巨大未满足的医疗需求，从而帮助改善或延长生命。自1885年成立以来，勃林格殷格翰一直是独立的家族企业，始终着眼长远发展，将可持续发展理念贯穿全价值链。公司在全球有近5.45万名员工，服务逾130个市场，致力于打造一个更健康、更可持续、更公平的未来。更多详情，请访问：www.boehringer-ingelheim.com。

抗体药物偶联物引进/卖出细胞疗法医药出海

100 项与 CUE-501 相关的药物交易

登录后查看更多信息